1 H MRS detection of glutamate predicts survival in pediatric medulloblastoma
Martin Wilson 1,2 , Simrandip K Gill 1,2 , Lesley MacPherson 2 , Martin English 2 , Theodoros N Arvanitis 2,3 , and Andrew C Peet 1,2
School of Cancer Sciences, University of
Birmingham, Birmingham, United Kingdom,
Children's Hospital NHS Foundation Trust, Birmingham,
of Digital Healthcare, WMG, University of Warwick,
Coventry, United Kingdom
Medulloblastoma is the most common malignant brain
tumour occurring in childhood and the diversity of
outcomes makes this a particularly challenging disease
to treat. In this study,
MRS was collected from 35 medulloblastoma patients and
metabolite biomarkers were investigated to stratify
high-risk patients. Glutamate was found to predict
survival, and validated prospectively.
HR-MAS was collected from a sub-set of patients and
agreement between in-vivo and ex-vivo results was found,
adding validation to the assignment of glutamate. The
identification of glutamate as a predictive biomarker of
survival in medulloblastoma provides a clinically viable
measure and multi-center reproduction is warranted.
This abstract and the presentation materials are available to members only;
a login is required.